A randomized trial of cilostazol versus ticlopidine for anti-platelet therapy after coronary artery stenting for prevention of restenosis

HONG Bin,QIAN Juying,FAN Bing

DOI: https://doi.org/10.3969/j.issn.1004-8812.2006.03.012

2006-01-01

Abstract:Objective To evaluate the efficacy and safety of cilostazol in comparison with ticolopide in the prevention of restenosis in patients with coronary stenting.Methods A total of 150 patients planed to stent implantation were randomly assigned to either cilostazol group(cilostazol 100mg twice daily,in addition to aspirin for 6 month) or to ticolopide control group(ticolopide 250 mg twice daily for 1 month,in addition to aspirin for 6 month).Angiographic follow-up was performed at 6 months,and clinical follow-up was continued up to 2 years.The angiographic end point was the minimal luminal diameter at follow-up as determined by quantitative coronary angiography.The primary clinical end points included death from any cause,myocardial infarction,the need for target lesion revascularization and new onset of stroke.Results The mean(±SD) minimal luminal diameters,net lumen gain and late lumen loss at follow-up were 2.24±1.16 mm,2.73±0.45 mm and 0.90±1.05 mm in the cilostazol group respectively,while in the ticolopide group were 2.04±1.24 mm,2.78±0.46 mm and 0.38±0.40 mm,respectively(all P values >0.05).Rates of restenosis(diameter of stenosis ≥50 percent) was 28.0% in cilostazol group and 36.7% in ticolopide group(P>0.05).Conclusion Aspirin plus cilostazol showed comparable antithrombotic effect as aspirin plus ticlopidine after elective coronary stenting and may serve as an alternative treatment for patients intolerable to ticlopidine.